2025-03-20 06:54:45
Latest Post
Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.
Suraj Estate Developers Ltd acquires Land Parcel at Shivaji Park, Dadar (West), Mumbai
Nawaz Modi Singhania steps down as Director
IKS Health wins additional Top Honors in 2025 Black Book Surveys in Clinical Documentation and Medical Coding
ZIM Laboratories Ltd receives Marketing Authorization for Dimethyl Fumarate (120 mg & 240 mg) Modified Release Capsules in Portugal, Europe
Research
Accumulate Simplex Infrastructures- Visibility improves - Elara Capital
Posted On : 2010-11-16 10:32:31( TIMEZONE : IST )
- Rating : Accumulate
- Target Price : INR488
- Upside : 6%
- CMP : INR461 (as on 12 November 2010)
Results below estimates; maintain 15% yearly growth guidance
SIL reported a meagre 2.6% rise in YoY revenues to INR10.5bn as the contribution from overseas projects declined for the third consecutive quarter - this time by a whooping ~53% to INR1.2bn. Operating margins too dropped, though marginally by 33bps YoY, owing to a 4.3% YoY rise in material consumption. Consequently, operating profits remained flat at ~INR1.1bn. Though interest and depreciation charges for the quarter remained largely in check, impacted by a poor operational performance, net profits slipped ~4% YoY to INR269mn.
Order backlog improves further, bags fresh jobs worth INR22.3bn
The order backlog as of Sep'10 2010 stood at ~INR130bn (2.7x FY11E revenues) excluding the potential L1 positions across new jobs worth INR12.2bn. The company has a bid pipeline for works worth INR387bn (including overseas bids) - clarity on which should emerge in subsequent quarters. With the private sector capex gaining momentum, we expect SIL to further add jobs worth ~INR40bn in the remaining two quarters of the fiscal.
Maintain Accumulate with a revised price target of INR488
Disappointed by a weak H1FY11 performance even against our conservative expectations, we tone down our earnings estimates for FY11 and FY12 by ~14% and 6.3% respectively. We remain skeptical on SIL's prospects despite a heartening pick up in domestic revenues and fresh order inflows since Q4FY10. The same explains our expectations of a meager 8.4% YoY revenue growth in FY11 vis-Ã -vis the management's guidance of 15%.
We roll forward our valuation metrics to FY12 and revise our target price downwards to INR488. We value SIL's core construction business at 13x FY12E earnings (~20% premium to industry peers) and overseas subsidiaries and Bhubaneshwar Chandikol BOT at 1.5x and 1.1x P/BV respectively. We maintain 'Accumulate' rating.
